​News 

 
Published: 24.02.2016

The ENCCA project (‘European network for cancer research in children and adolescents’) successfully ended on 31st December 2015. This 5-years’ project achieved its mission by efficiently structuring collaboration within the paediatric oncology community in Europe. Funded by the European Union 7th Framework Programme for Research, ENCCA was driven by 34 partners of 27 paediatric oncology institutions in 11 European countries led by SIOPE and by CCRI – St. Anna Kinderkrebsforschung (Austria).ENCCA

Last 17‐18 December 2015, the 5th and final ENCCA General Assembly took place in Brussels, giving an opportunity to summarise the final results of the intensive project activities, to highlight partners’ successes and to learn from each other’s efforts in the field of paediatric haematology-oncology research.

Over the past years, SIOPE and ENCCA changed the landscape of paediatric haematology-oncology research in many ways. The SIOPE Clinical Research Council (SIOPE CRC, formerly known as ECRC) is an important step forward in the ENCCA objective to establish a European ‘Virtual Institute of Paediatric Oncology’. The second day of the General Assembly was marked by the official inauguration of the revised SIOPE CRC, a key decision-making body aiming to convey the strong voice of all European Clinical Trial Groups and National Societies of Paediatric Oncology at the European level.

ENCCA

The overall objective of ENCCA was to efficiently structure childhood cancer research in Europe. Project partners successfully investigated several aspects related to paediatric cancers from every angle, from developing models for bio-banking and genomic analysis to guide innovative targeted therapy development to new methodologies for adaptive clinical trial designs for rare diseases, from specific clinical studies on bone sarcoma, leukaemia and very rare tumours to risk adaptation of therapeutic strategies in malignant solid tumours, from clinical epidemiology to handling the delicate transition from paediatric to adult oncology.

In particular, ENCCA supported the development of the ‘Survivorship Passport’, a tool to ensure high-quality long-term follow-up for adult survivors of paediatric cancer. This important initiative, developed by SIOPE partners, addresses the current lack of information on many survivors’ medical history – particularly critical as children become adults or as they move to another country – by providing relevant information on their medical history, and raising awareness of the potential risks or late effects stemming from the disease and treatment (more information on the Survivorship Passport here). This innovative tool is starting to be integrated in National Cancer Plans, as it has been the case of Austria in 2014.

ENCCA3

By bringing together and integrating the relevant expertise and viewpoints of all relevant stakeholders, the all-encompassing activities within the project resulted in a fast-growing community.

ENCCA helped to build very strong relationships with European parent and parent advocates, which resulted in a Memorandum of Understanding between SIOPE and the Europe regional committee of Childhood Cancer International (CCI), the successor of the ENCCA Parent and Patient Advocacy Committee (PPAC).

The project also promoted effective partnerships with industry via the CDDF-SIOPE-ENCCA-ITCC Multi-stakeholder “Paediatric Oncology Platform”. Representatives from regulatory bodies, academia, the pharmaceutical industry, parents and policymakers cooperate on a permanent basis within the 4 working groups of this Platform, and work on concrete proposals to improve new oncology drug development for children and adolescents.

In the course of the past years, SIOPE and ENCCA made several efforts to integrate and showcase ENCCA in all its initiatives at the European level. The project had a strong impact on European Policies: to name just a few, the ENCCA Project Coordinator, Activity Coordinators and other partners contributed to the effective revision of the European Clinical Trial Regulation, they are now expressing their views on the Paediatric Medicines Regulation (see article in this newsletter) as well as to the forthcoming new European Data Protection Regulation, and were represented as speakers at major EU policy events.

ENCCA’s visibility and success enabled the launch of ExPO-r-Net, a project focusing on the access to quality cross-border healthcare and expert advice to all paediatric patients in Europe. By building a European Reference Network for Paediatric Oncology, this ‘European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment’ addresses the existing difference in healthcare capabilities and in children’s survival across Europe (www.ExPOrNet.eu).

Over the last 5 years ENCCA experts and partners successfully defined the very much needed SIOPE Strategic PlanA European Cancer Plan for Children and Adolescents’, which will ensure long-term sustainability of ENCCA achievements. This reference document will give directions to the community in the years to come to increase cure rates, improve quality of survivorship, and foster multi-stakeholder dialogue and cooperation to achieve the best results.

ENCCA4

More information: 

 
Published: 12.07.2015

The final ENCCA General Assembly & SIOPE CRC Meeting will take place on 17-18 December 2015 in Brussel, Belgium.

All ENCCA partners are warmly invited to attend, as this will be the only occasion where they can show the final results of your hard work during all these years of ENCCA, to learn from each other’s efforts and to jointly discuss follow up plans for the future.

Please find below some more information on the event: 


 
Published: 20.10.2015

SIOPE – MAC Launch:

European Cancer Plan for Children and Adolescents






Wednesday 18th November 2015

(12:30 – 14:30, starting with a networking lunch at 12:00)

European Parliament, Brussels, Belgium – Hosted by MEP Mr Alojz Peterle, MAC President

 

REGISTER HERE

PRELIMINARY PROGRAMME

 

We look forward to welcoming ENCCA partners at the upcoming launch at the EU-policy level of the SIOPE European Cancer Plan for Children and Adolescents.

 

SIOPE is joining efforts with the Members of the European Parliament Against Cancer (MAC) to unveil this long-term vision of the entire child cancer community at the EU-level, seeking cooperation with policymakers in order to increase in the cure rate, improve the quality of survivorship, and foster multi-stakeholder dialogue and cooperation for the best results.

 

The SIOPE – MAC event will present the European Cancer Plan for Children and Adolescents – from the extensive consultation and consensus-building process leading up to its formulation and the prominent role of parents, patients and survivors, to the best ways towards implementation through joint efforts. Collaborative models and enabling EU initiatives will be addressed, in particular on:

  • Eradicating inequalities in access to treatment, care, and expertise
  • Boosting innovation in medicines development
  • Securing optimal organisation of follow up care for survivors

 

More information:

 
Published: 10.05.2015

In view to ensure the sustainability of the ENCCA project, SIOPE just launched a 10 years Strategic Plan to increase both cure rate and quality of cure, as well as to tackle inequalities across Europe.

The Plan was first elaborated within the ENCCA network of excellence (European Network for Cancer research in Children and Adolescents, FP7 2011-2015), and enriched through the contributions of SIOPE members and partners, as well as parents, patients, and survivors' advocates.At the conference 'Joining efforts for a brighter future for children and adolescents with cancer – The European roadmap to Horizon 2020' (18-19 September 2014, Brussels) approximately 160 participants from 31 countries publicly endorsed the proposal and called for a European Cancer Plan for Children and Adolescents that would  address both clinical care and research.

The ultimate goal of the SIOPE Strategic Plan is to increase the survival that is free from disease and late effects- after ten years from the disease (and beyond) by achieving seven key objectives. Cross-tumour platforms and projects are being set up to facilitate the Plan's implementation spanning the critical variables influencing success, such as outcomes research to monitor progress made, a platform to provide radiotherapy quality assurance, a multi-stakeholder platform with academia, industry, regulators and parents to improve paediatric development of new oncology drugs, as well as a research program to address ethics and psycho-social aspects of childhood cancer.

A  European Reference Network will be created to facilitate cross-border healthcare and access to expertise for paediatric cancer patients across Europe no matter where they live. An efficient e-Health infrastructure is set to support such system building on the ExPO-r-Net project.

The 'Oncopolicy' programme will advocate better EU policies to address the needs of young people with cancer. Indeed, SIOPE will help the implementation of cross border clinical trials within the new Clinical trial regulation and advocate for a Data Protection regulation that will not jeopardize research efforts for children and adolescents while assuring privacy to all citizens. The implementation of the EU paediatric medicine regulation must urgently be improved in order to adequately address the needs of children with cancer. Specific new incentives might be required.

SIOPE will steer and coordinate the effective implementation of this Plan, together with all stakeholders; existing partnerships will be strengthened with adult oncologists as well as professionals from other continents, while public-private partnerships – recognising the specificities of paediatric haematology-oncology – will be established with industry. SIOPE established a partnership with Childhood Cancer International, the federation of parents, patients and survivors organizations to implement the Plan.

The SIOPE Strategic Plan has been officially presented during the European Cancer Congress (25-29 September 2015, Vienna, Austria), and will be also further discussed at the EU-policy level during an event which will take place on 18th November 2015 at the European Parliament in Brussels, Belgium (more information: www.siope.eu/?p=3428).

We trust that this Plan will inspire many future initiatives in the field. It has to date already achieved an important milestone of broad multi-stakeholder consensus and we look forward to working with all relevant stakeholders to make it a success, preparing a brighter future for children and adolescents with cancer in our region.

Discover the SIOPE European Cancer Plan for Children and Adolescents here: www.siope.eu/SIOPE_StrategicPlan2015
 
 
Published: 07.08.2015

ENCCA General Assembly.jpg

The 2015 ENCCA General Assembly and ECRC meeting took place last 15th-16th January in the Belgian capital. This was the 4th General Assembly of the project, and the second day of the meeting also hosted a joint ENCCA-ECRC meeting which focused on the most urgent aspects concerning the implementation of the EU Clinical Trial Regulation.

This was the perfect occasion to celebrate the major achievements obtained by ENCCA after four years as, within this timeframe, project partners managed to build a solid and well renowned network of excellence for paediatric cancer research. Last January meeting participants made an assessment of the efficacy and quality of the results achieved so far, having in mind the original project aim to improve the quality of childhood cancer healthcare, the accessibility of paediatric drugs and innovative therapies, as well as the quality of life of survivors across Europe.

Several European-wide councils and committees have been created thanks to the ENCCA project: among the many, the European Clinical Research Council for paediatric oncology (ECRC), which managed to voice the common harmonised agenda of the clinical and research community at the European level; the Ethics' Advisory Committee (EAC), that covered very important aspects linked to treatment and follow-up; and the Parent Patient Advocacy Committee (PPAC), which represented an opportunity to strongly express paediatric oncology patients' needs in Europe. All these and other bodies will be integrated in the SIOPE structure after the end of ENCCA, in order to ensure the sustainability of the project achievements on the long-term.

The contribution of ENCCA partners to the implementation of several advocacy campaigns led by SIOPE, such as the amendments to the Clinical Trial Regulation, has been also underlined during this meeting. Finally, participants also reminded the importance of the outcome of the SIOPE-ENCCA Conference in 2014, an important event which effectively opened horizons for a shared ambitious vision on the future of paediatric oncology in the next decade.

All presentations showed during the last ENCCA General Assembly and ECRC meeting have now been made available for partners on the project intranet (for more information, please contact the ENCCA Project Manager, Mr Zoltán Dobai encca@ccri.at).

 
Published: 07.08.2015

​ENCCA Closing Conference: Save the Date
17-18 December 2015, Brussels, Belgium

ENCCA Closing Conference.png

The final event of the ENCCA project will take place at the Renaissance Hotel in Brussels, and all ENCCA partners are kindly invited to mark the following date on their calendar: Thursday 17th and Friday 18th December 2015.

This unique event will be the only occasion for partners to show the final results of their strenuous work performed within the project, to learn from each other and to jointly discuss plans for the future. More practical information will be circulated closer to the event date, by email and on the ENCCA website (www.encca.eu).

 
Published: 20.04.2015

SIOPE Scholarships Grants – Application

The European Society for Paediatric Oncology, SIOPE will award a total of five (5) scholarships to assist young Paediatric Oncologists to attend the 18th ECCO-40th ESMO- European Cancer Congress in Vienna. Preference will be given to those actively participating in the meeting. The scheme is designed to assist younger members particularly members from Eastern European Countries and members less than 35 years old, who otherwise would have major difficulties in securing alternative funding.

This grant will be used to assist with the cost of attending the Congress, and each Fellowship will cover:

  • The Congress registration fee;
  • Up to maximum 400 EUR for accommodation;
  • Up to maximum 400 EUR travel costs, based on an apex return airfare in economy class;
  • Reimbursement after the Congress.

To be considered for a fellowship grant, the applicant should meet the following requirements:

  • Submit an abstract for the European Cancer Congress 2015. Applicants whose abstracts have been accepted for an oral or poster presentation at the Congress will be considered first.
  • The online fellowship grant application form should ONLY be submitted ONCE irrespective of the number of abstracts you submit.
  • Be under the age of 40 and have a primary focus in clinical, translation or basic research in paediatric haematology oncology
  • Provide a letter of support from the Head of the Department/Organisation stating that the applicant is not the recipient of any other financial support, including a copy of the submitted abstract(s). Only a PDF file will be accepted for upload.
  • Provide a two page CV (including date of birth).
  • Applicants must be fluent in English.

Please complete the online application form here. If you have NOT yet submitted an abstract for the congress click here.

Please note that the Abstract Submission is open until 28 April 2015. The deadline for receipt of applications is 5 May 2015. Applicants will be notified by email regarding the status of their application end June 2015.

 
Published: 20.04.2015

The European Cancer Congress (ECC 2015) is a biennial congress which combines the efforts of the most important European oncology professionals with the aim of improving the treatment and care of all cancer patients.

The European Cancer Congress will provide ideal surroundings for participants to leverage knowledge, promote education and build awareness about oncology – placing the patient at the heart of all our efforts and discussions. Partner organisations include: ECCO, ESMO, ESTRO, ESSO, EACR, EONS, SIOPE,  representing a  multidisciplinary approach to cancer treatment and care.

SIOPE members – you benefit from preferential registration rates!

Not a SIOPE member? Join today and you too can save on registration for ECC 2015. Plus, you’ll be able to access the exclusive SIOPE members’ lounge during the congress in Vienna.

All registration and congress-related questions should be made directly to ECCO, the ECC 2015 organisers.

Register now for ECC 2015

Submit an abstract for ECC 2015

Access the searchable programme


Deadlines

DeadlineDate
Early rate registration9 Apr 2015
Abstract submission 28 Apr 2015
Fellowship grant application 5 May 2015
Regular rate registration4 Aug 2015
Late-breaking abstract submission5 Aug 2015
Late rate registration18 Sept 2015


Venue

Messe Wien Exhibition & Congress Centre
Messeplatz 1
1021 Vienna, Austria

 
Published: 20.04.2015

​The Belgian ‘Vlaamse Liga tegen Kanker’ organised a symposium on translational bioinformatics in cancer research on 2nd April 2015 in Ghent (Belgium). It has been preceded by a workshop for PhD/post-docs on 1st April 2015, in the framework of the lectureship of Katleen De Preter entitled: “Bioinformatics for future precision medicine in cancer treatment”.

More information:

 
Published: 20.04.2015

Cancer in children and young people remains an important global public health issue and one that only cooperation between all stakeholders – health professionals, researchers, parents, patients and survivors, as well as political bodies, regulatory agencies, pharmaceutical companies, and fundraising charities – can overcome.

As part of its aim to integrate all stakeholders from the European paediatric oncology community, SIOPE is therefore further developing its close partnership with engaged parent/patient and survivors advocates from all over Europe.

Over the years SIOPE has established a direct contact and strong collaboration with the representatives of European parents, patients and survivors through the European branch of Childhood Cancer International (CCI) and the Parent and Patient Advisory Committee (PPAC, established within the ENCCA Project).

CCI logo version 421b with text and gold ribbon straight 

In particular, the international body representing families of children with cancer, formerly known as ICCCPO, changed its name last year and it is now called Childhood Cancer International (CCI). At the last SIOP Congress in Toronto, CCI also renewed its Board and Ms Carmen Auste from the Philippines was elected as a new President (for Europe, Luisa Basset from Spain was elected). This year, CCI launched a very successful Global Campaign to mark International Childhood Cancer Day (15th February).  This collaborative campaign aimed to express support and promote deeper understanding of all issues impacting on children/adolescents with cancer, the survivors, their families and the society as a whole. As a close partner in the same fight for a better futture for children and adolescents with cancer, SIOPE organised the 2015 edition of the its International Childhood Cancer Awareness Day at the European Parliament (3rd February 2015, Brussels, Belgium). Our Society advocated better EU legislation for paediatric oncology research by particularly focusing on ‘Balancing Personal Data Protection and Research Progress: The Case of Childhood Cancer’.

More information

 
Published: 20.04.2015

SIOP 2015

The 47th Congress of the International Society of Paediatric Oncology (SIOP) will take place next 8-11 October 2015 in Cape Town, South Africa.

ENCCA will be present on this occasion with a stand, representing its multidisciplinary vision on how to improve better and more equitable cure for childhood cancer in Europe.

ENCCA contributes to the global agenda of SIOP, in order to improve and optimise treatments throughout the world. In keeping with the tradition of previous SIOP congresses, the scientific programme will comprise of plenary sessions, guest lectures, committee/group sessions, meet the expert sessions, free and proffered paper sessions.

More information:

 
Published: 20.04.2015

With 35,000 new cases every year, childhood cancer is an urgent public health issue in Europe. Access to care is unequally available across the region and, in spite of the progress achieved, cancer remains the leading cause of disease-related death for children beyond one year of age.

Under the coordination of the European Society for Paediatric Oncology (SIOPE), the European Paediatric Haemato-Oncology community is currently making the final fine-tuning of a shared ‘Roadmap for children and adolescents with cancer’. This document aims to increase the rate and the quality of cure in the next decade by targeting 7 major objectives:

  1. Introducing safe and effective innovative treatments into multidisciplinary standard care;
  2. Driving therapeutic decision by improved risk classification, the use of molecular characteristics and precision medicine;
  3. Increasing knowledge of tumour biology and speeding up translation to benefit patients;
  4. Increasing equal access across Europe to standard care, expertise and clinical research;
  5. Addressing the specific needs of teenagers and young adults;
  6. Addressing the quality of survivorship;
  7. Understanding the causes of paediatric cancers and setting prevention where possible.

Developed from consolidated pan-European expertise and in cooperation with patient groups, the strategy is the outcome of the coordinating efforts of SIOPE and ENCCA. At the recent SIOPE-ENCCA Conference (18-19 September 2014, Brussels, Belgium) it successfully achieved broad multi-stakeholder consensus from across the spectrum of cancer actors.

Set to strongly influence the paediatric haemato-oncology landscape, the initiative is the outcome of a close partnership among all involved stakeholders – including experts at the global level – and demonstrates commitment to making progress for children and adolescents with cancer. Some of the platforms and cross-tumour programmes identified in it are already operational and – following the successful endorsement of the SIOPE-ENCCA-ICCCPO Electoral Manifesto – the SIOPE community has established closer partnerships with parent/patient/survivor advocates, adult oncology, industry and paediatric haemato-oncology in other continents. SIOPE is in the process of initiating the programmes identified therein to ensure effective implementation.

More information

 
Published: 16.02.2015
_97A1951
International Childhood Cancer Day - ICCD (15th February) is a key date for all childhood cancer patients, their families and all those who care for them. This is why SIOPE this year effectively raised awareness on the needs and challenges faced by children and adolescents with cancer in different ways.

SIOPE started by advocating better EU legislation for paediatric oncology research, at the heart of finding better and more effective cures for childhood cancer. The 2015 edition of the SIOPE's influential International Childhood Cancer Awareness Day (3rd February 2015, European Parliament, Brussels, Belgium) focused on 'Balancing Personal Data Protection and Research Progress: The Case of Childhood Cancer'. Hosted by our long-standing supporter, Member of the European Parliament Ms. Glenis Willmott, the event gathered more than 80 participants from all over Europe, who debated the projected consequences of the new EU Data Protection Regulation on childhood cancer research (see SIOPE Press Release, 4/2/2015).

On 5-6 February ENCCA co-organised the 3rd Paediatric Oncology Conference 'Prioritisation in Paediatric Oncology Drug Development' in Vienna, Austria, the 3rd meeting of an ongoing series of biennial conferences organised in partnership with ITCC, CDDF and SIOPE. This multi-stakeholder event promoted progress in the field of paediatric oncology drug development through input from all concerned stakeholders: regulatory bodies, academia, the pharmaceutical industry, parents and policymakers. Proposals from a Platform on Paediatric Oncology, created in December 2013 to improve drug development for children and adolescents with cancer (see article on European Journal of Cancer), were discussed during the conference.

SIOPE fully supported and engaged in the Global ICCD Campaign launched by Childhood Cancer International, the international body representing families of children with cancer, and close partner of SIOPE (see here). This collaborative campaign aimed to express support and promote deeper understanding of all issues impacting on children/adolescents with cancer, the survivors, their families and the society as a whole.

Prof Gilles Vassal, the President of SIOPE, spent many days around the date 15th February in raising awareness on the need for better and more equitable cure for childhood cancer in Europe.
After having led our European Parliament event on 3rd February, he was invited as a key guest of the French TV programme "Le magazine de la santé" (14'26'') on 12th February 2015, together with Ms Patricia Blanc, parent advocate from Imagine for Margo and strong partner of SIOPE.

On 13rd February he also released an interview to the Swiss radio and, on the occasion of the International Childhood Cancer Day, Prof Vassal took part in two outstanding events:

_DSC0013

 
 
Published: 22.09.2014


Joining Efforts for a Brighter Future for Children and Adolescents with Cancer

The European Roadmap to Horizon 2020

18-19 September 2014, Brussels, Belgium (Renaissance Brussels Hotel)

Webpage

 
Published: 30.07.2014

​The Spanish Association of Adolescents and Young Adults with Cancer (AAA) and ENCCA organized last 27 and 28 March the Second International Course on Adolescents and Young Adults with Cancer in Madrid.

The aim of the course was to introduce the Association, specially to create professional awareness and highlight the importance of providing specialized attention (medical, social and psychological) to these patients.

More information:

Video presentations from the 2nd International Course on Adolescents and Young Adults with Cancer